0001209191-23-058818.txt : 20231215 0001209191-23-058818.hdr.sgml : 20231215 20231215171021 ACCESSION NUMBER: 0001209191-23-058818 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231213 FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stuart Iain CENTRAL INDEX KEY: 0001727756 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 231491282 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-13 0 0001566044 VYNE Therapeutics Inc. VYNE 0001727756 Stuart Iain C/O VYNE THERAPEUTICS INC. 685 ROUTE 202/206 N, SUITE 301 BRIDGEWATER NJ 08807 0 1 0 0 Chief Scientific Officer 0 Common Stock 2023-12-13 4 A 0 62500 0.00 A 71555 D Stock Option (right to buy) 2.70 2023-12-13 4 A 0 62500 0.00 A 2033-12-12 Common Stock 62500 62500 D Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Mutya Harsch, attorney-in-fact for Iain Stuart 2023-12-15